Observational studyJournal of gastrointestinal cancer2025
A Prospective Observational Study on Compliance with Enhanced Recovery Pathways and Their Impact on Postoperative Outcomes Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.
Observational study in Journal of gastrointestinal cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Enhanced Recovery After Surgery in Cytoreductive Surgery With HIPEC: Implementation and Outcomes From a High-Volume Tertiary Centre in a Lower-Middle Income Country.Journal of surgical oncology · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEnhanced recovery pathways have been shown to improve postoperative morbidity and reduce hospital stay across various surgical settings. However, the implementation of Enhanced Recovery After Surgery (ERAS) pathways in cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) is often challenging and varies between institutions. We evaluated the impact of ERAS compliance on postoperative outcomes and return to intended oncological therapy (RIOT).
methodsAll consecutive patients operated for CRS-HIPEC between May 2021 and August 2023 were included in the study. Compliance with 30 ERAS components was collected. Postoperative complications were categorized using the Clavien-Dindo (CD) classification. Patients were followed for 30 days post-surgery to assess readmissions and delays in RIOT. Pearson correlation analysis evaluated the relationship between ERAS compliance and CD grading, length of hospital stay, readmissions, and RIOT delays. Logistic regression analysis was done to evaluate the association between percentage compliance to ERAS components and postoperative morbidity and length of hospital stay.
resultsAmong 150 patients, the average compliance to ERAS components was 77.6%. There was a significant negative correlation between ERAS compliance and postoperative morbidity (r = - 0.512, p < 0.001) and RIOT (r = - 0.469, p < 0.001). Compliance with preoperative (r = - 0.222, p = 0.006) and postoperative factors (r = - 0.533, p < 0.001) significantly impacted postoperative morbidity and RIOT. Patients with less than 71.6% compliance had higher morbidity (χ
conclusionHigher compliance is linked with reduction in postoperative morbidity, shorter hospital stays, and timely RIOT. These findings reinforce the safety profile of ERAS pathway in CRS-HIPEC. However, multicenter studies are needed to support these findings. REGISTRY: Clinical Trial Registry of India (CTRI/2021/02/031151).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.